Recruiting

Cisatracurium & Neostigmine vs. Rocuronium & Sugammadex

Sponsor:

The University of Texas Medical Branch, Galveston

Code:

NCT07203287

Conditions

Post Operative Pulmonary Complications

Neuromuscular Blockade

General Anesthesia

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Rocuronium

Cisatracurium

Sugammadex

Neostigmine

Study Details

Brief summary:

The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is

"The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."

Conditions

Post Operative Pulmonary Complications

Neuromuscular Blockade

General Anesthesia

Study ID

NCT07203287

Start date

Aug 26, 2025

Status verified date

Feb, 2026

Completion date

Aug 26, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • The subject is able and willing to provide and sign informed consent
  • The subject must be between 18 and 80 years of age
  • The subject should have chronic kidney disease as defined by glomerular filtration rate
  • The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade

Exclusion Criteria:

  • Any patient under the age of 18
  • Any patient over the age of 80
  • Any patient with end stage renal disease
  • Any patient requiring dialysis
  • Patients presenting for Renal Transplantation
  • Pregnant Female
  • Any patient in the correctional system
  • Urgent or Emergent procedure
  • The surgery requires intubation post-operatively
  • Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine

Study Design

Enrollment

490 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Rocuronium and Sugammadex (RS) Group

The participants will be given rocuronium and sugammadex as part of one of the standard regimens of neuromuscular blockade and reversal.

active comparator: Cisatracurium and Neostigmine (CN) Group

The participants will be given cisatracurium and neostigmine as part of one of the standard regimens of neuromuscular blockade and reversal.

Interventions

Rocuronium

Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

Cisatracurium

Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

Sugammadex

Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

Neostigmine

Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

Primary outcome measure

  • Post Operative Pulmonary Complications (PPCs) [ Time Frame: 7 days ]

Central Contacts and Locations

Central contacts

Michael Kinsky, MD

409-772-1011mkinsky@utmb.edu

Locations

University of Texas Medical Branch

Recruiting

Galveston, Texas, United States, 77554

Contacts

Michael Kinsky, MD

409-772-1011mkinsky@utmb.edu

More Information

Sponsor

The University of Texas Medical Branch, Galveston

Last update posted

Feb 23, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston on 2026-02-23.